Alzheimer's Disease Center

 

Lexington Clinic Studies

STUDY OPPORTUNITIES:

	Overview

	UK ADC Affiliated Studies

	UK ADCS Trials

	UK Aging Studies

	Lexington Clinic Studies

	Neuroimaging Studies of Depression in Parkinson's Disease

	Research Participation Opportunities (pdf)

	UK ADC Affiliated Studies Flyer (pdf)

Research Opportunities Conducted in Collaboration between the Lexington Clinic and the UK Alzheimer's Disease Center and the Sanders-Brown Center on Aging

• ROZEREM for the treatment of sleep disturbances in moderate to severe AD
  • Pharmaceutical trial conducted by Takeda Global Research and Development Center http://clinicaltrials.gov/ct/show/NCT00325728?order=48
  • Greg Cooper, M.D., Ph.D. http://www.mc.uky.edu/neurology/cooper.html serves as the principle investigator
  • Funding: Takeda Global
  • UK IRB#
  • Rozerem is a non-addictive sleep aid that may help with sleep disorders associated with Alzheimer's disease, and with little effect on cognitive function, unlike other sleep medicines that can further impair memory and thinking function in AD
  • For more information or to enroll, contact Marie Smart at 859-323-6729

• High Dose Aricept© (donepezil) for the treatment of moderate to severe Alzheimer’s disease
  • Pharmaceutical trial conducted by Pfizer-Esai
  • Greg Cooper, M.D., Ph.D. http://www.mc.uky.edu/neurology/cooper.html serves as the principle investigator
  • Funding: Pfizer-Esai
  • UK IRB#
  • The current maximum approved dose of Aricept© (donepezil)was determined in studies of persons with mild to moderate Alzheimer’s disease. Higher doses may be more beneficial in persons with worsening Alzheimer’s disease given the progression of brain cells as the disease progresses. This trial hopes to establish the optimal doses for use in the mid and later stages of disease to maximize quality of life and improve symptom control for persons with Alzheimer’s disease.
  • For more information or to enroll contact, Marie Smart at 859-323-6729